Event Calendar
Prev MonthPrev Month Next MonthNext Month
Treatment of Psychotic Disorders I via NMSU
Saturday, January 21, 2023, 9:00 AM to Sunday, January 22, 2023, 6:00 PM CST
Category: Events

Treatment of Psychotic Disorders | via NMSU
(13.5 Hours)

The Iowa Psychological Association is pleased to partner with New Mexico State University's Clinical Psychopharmacology Post- Doctoral Masters Degree Program to offer Continuing Education (CE) training to IPA members.

Treatment of Psychotic Disorders

Credit Hours: 13.5 CEUs (Provided by NMSU, Sponsored by APA) NMSU is approved by the American Psychological Association to sponsor continuing education for psychologists. NMSU maintains responsibility for the program and its content

Location: Online

January 21 & 22, 2023
9:00am - 6:00pm CST

David Shearer, Ph.D., MSCP

$300: IPA Member
$200: IPA Lifetime Member
$200: IPA ECP Member
$130: IPA Retired Member
$0: IPA Student Member
$450: Non-Member

About This Workshop

In this training module we continue our study of clinical psychopharmacology through the instruction of Schizophrenia Spectrum, Other Psychotic Disorders, and Antipsychotic Drugs. Common characteristics and etiology are reviewed. Special emphasis is placed on the medication compliance, efficacy, safety, and therapeutic drug monitoring. Moreover, this intensive study includes the holistic treatment of psychosis from a biopsychosocial model of care.  Special consideration is given to three groups of distinctive antipsychotic drugs. And their pharmacology and clinical uses. Significant medical issues associated with antipsychotic medications will be explored. In addition, the trainee will learn about modifications in treatment plans indicated when a biopsychosocial perspective is taken. With appropriate adjustments in consideration of treating individuals of across all areas of diversity.

Learning Objectives

Participants will be able to:
  1. Generalize three etiological perspectives of Psychotic Disorders.
  2. Name three Preclinical Models of Schizophrenia.
  3. Contrast four major dopaminergic pathways in the central nervous system associated with psychotic disorders.
  4. Break down two aspects of the Dopamine (DA) Imbalance Hypothesis.
  5. Differentiate at least two effects of various antipsychotic drugs on the positive and negative symptoms of schizophrenia.
  6. Evaluate at least two other neurotransmitters associated with psychosis. Name three groups of antipsychotic/neuroleptic drugs.
  7. Diagnose the one (main) receptor in the brain believed to be responsible for the mechanism of action of most antipsychotic medication.
  8. Index at least four disturbing neuroendocrine side effects associated with antipsychotic medication and prolactin (pituitary gland) release.
  9. Name four common side effects of antipsychotic medication. Recall two common adverse drug reactions with antipsychotic medication.
  10. Interpret two drug-drug interactions with antipsychotic medication.
  11. Describe two the biochemical and physiological basis of adverse reactions with antipsychotic treatments.
  12.  Name and discuss how to manage three medical issues that arise from their use.
  13. Recite five hallmark features (FEVER acronym/mnemonic) Neuroleptic Malignant Syndrome.
  14. Distinguish three ACUTE movement disorders associated with Extrapyramidal Side Effects (EPSE).
  15. Distinguish three CHRONIC movement disorders associated with EPSE.
  16. Identify three techniques for assessing their severity of various antipsychotic drugs.
  17. Practice with the use of the administration of two rating scales assessing those side effects (e.g. AIMS, BMI).
  18. Name one significant drug used to augment antipsychotic medication and reduce EPSE. And describe it’s mechanism of action.
  19. Compile at least 5 monitoring parameters when using a Clozapine/Clozaril protocol.
  20. Examine two cost-benefit ratios of psychotropic use for adult, child, adolescent and elderly patients with psychotic disorders.
  21. Become familiar with at least two current treatment algorithms for the management of psychotic disorders and their limitations.
  22. Classify at least three antipsychotics that have FDA approval for children, adolescents, and elderly.
  23. Select at least two antipsychotics are used that are used off-label in the treatment of children, adolescents and the elderly.
  24. Using evidenced based medicine, across three patient case vignettes presented during the training, select the most appropriate medication(s).
  25. Compare how the biopsychosocial perspective is taken with appropriate adjustments when considering at least three avenues of patient diversity.
  26. Explain the biochemical mechanisms underlying the pharmacological efficacy of the three generations of antipsychotic drugs.

Click here to register

Course Materials and Continuing Education

NMSU will email registrants course materials, and a link to join the live training two business days before the training.

Upon completion of the training, NMSU will email registrants the training evaluation. Upon completion of the training evaluation, the NMSU will email the registrant the CE certificate.

Refund and Cancellation Policy

We understand, sometimes things come up!

IPA will offer a full refund to registrants who cancel their registration 7 days prior to an event/course. If a registrant would like to cancel their registration within 7 days of the event, no refund will be offered.

Contact: Suzanne Hull, [email protected]